MALAT1 and glioma: In a prognostic meta-analysis of 40 studies, MALAT1 expression predicted poor overall survival in patients with glioma, with a significant pooled hazard ratio of 2.32 (95% CI, 1.64–3.27; p < 0.001) [58].